This article may be too technical for most readers to understand. Please help improve it to make it understandable to non-experts, without removing the technical details. (February 2015) (Learn how and when to remove this template message)
|A man with aniridia|
|Classification and external resources|
Aniridia is the absence of the iris, usually involving both eyes. It can be congenital or caused by a penetrant injury. Isolated aniridia is a congenital disorder which is not limited to a defect in iris development, but is a panocular condition with macular and optic nerve hypoplasia, cataract, and corneal changes. Vision may be severely compromised and the disorder is frequently associated with a number of ocular complications: nystagmus, amblyopia, buphthalmos, and cataract. Aniridia in some individuals occurs as part of a syndrome, such as WAGR syndrome (kidney nephroblastoma (Wilms tumour), genitourinary anomalies and intellectual disability), or Gillespie syndrome (cerebellar ataxia).
The AN2 region of the short arm of chromosome 11 (11p13) includes the PAX6 gene (named for its PAired boX status), whose gene product helps regulate a cascade of other genetic processes involved in the development of the eye (as well as other non-ocular structures). This PAX6 gene is around 95% similar to the pax gene found in zebrafish, a creature whose ancestors diverged from human evolutionary development around 400 million years ago. Thus the PAX6 gene is highly conserved across evolutionary lineages.
Defects in the PAX6 gene cause aniridia-like ocular defects in mice (as well as Drosophila). Aniridia is a heterozygous disorder, meaning that only one of the two chromosome 11 copies is affected. When both copies are altered (homozygous condition), the result is a uniformly fatal condition with near complete failure of entire eye formation. In 2001, two cases of homozygous aniridia patients were reported; the fetuses died prior to birth and had severe brain damage. In mice, homozygous small eye defect (mouse Pax-6) leads to loss of the eyes and nose and the murine fetuses suffer severe brain damage.
Aniridia may be broadly divided into hereditary and sporadic forms. Hereditary aniridia is usually transmitted in an autosomal dominant manner (each offspring has a 50% chance of being affected), although rare autosomal recessive forms (such as Gillespie syndrome) have also been reported. Sporadic aniridia mutations may affect the WT1 region adjacent to the AN2 aniridia region, causing a kidney cancer called nephroblastoma (Wilms tumor). These patients often also have genitourinary abnormalities and intellectual disability (WAGR syndrome).
Several different mutations may affect the PAX6 gene. Some mutations appear to inhibit gene function more than others, with subsequent variability in the severity of the disease. Thus, some aniridic individuals are only missing a relatively small amount of iris, do not have foveal hypoplasia, and retain relatively normal vision. Presumably, the genetic defect in these individuals causes less "heterozygous insufficiency," meaning they retain enough gene function to yield a milder phenotype.
- Online Mendelian Inheritance in Man (OMIM) 106210 AN
- Online Mendelian Inheritance in Man (OMIM) 106220 Aniridia and absent patella
- Online Mendelian Inheritance in Man (OMIM) 106230 Aniridia, microcornea, and spontaneously reabsorbed cataract
- Online Mendelian Inheritance in Man (OMIM) 206700 Aniridia, cerebellar ataxia, and mental deficiency (Gillespie syndrome)
Molecular (DNA) testing for PAX6 gene mutations (by sequencing of the entire coding region and deletion/duplication analysis) is available for isolated aniridia and the Gillespie syndrome. For the WAGR syndrome, high-resolution cytogenetic analysis and fluorescence in situ hybridization (FISH) can be utilized to identify deletions within chromosome band 11p13, where both the PAX6 and WT1 genes are located. 
In May 2018, the U.S. Food and Drug Administration approved the CustomFlex Artificial Iris, the first synthetic iris for use in adults and children with congenital aniridia or iris defects related to other conditions, such as albinism, traumatic injury, or surgical removal due to ocular melanoma. The artificial iris is a surgically implanted device made of thin, foldable, medical-grade silicone and is custom-sized and colored for each individual patient. The prosthetic iris is held in place by the anatomical structures of the eye or, if needed, by sutures.
- Lang, K (2007). Ophthalmology: A Pocket Textbook Atlas (2nd ed.). Thieme. p. 208. ISBN 1-58890-555-1.
- Singh, Daljit; Arun Verma (17 January 2008). "Aniridia". eMedicine. Retrieved 2 February 2010.
- Lee H, Khan R, O'Keefe M (November 2008). "Aniridia: current pathology and management". Acta Ophthalmol. 86 (7): 708–15. doi:10.1111/j.1755-3768.2008.01427.x. PMID 18937825.
- Gehring, W. J. (2001). "The genetic control of eye development and its implications for the evolution of various eye-types". Zoology. 104 (3–4): 171–181. doi:10.1078/0944-2006-00022.
- Neethirajan G, Solomon A, Krishnadas SR, Vijayalakshmi P, Sundaresan P. (2009). "Genotype/phenotype association in Indian congenital aniridia".Indian J Pediatr 76 (5):513-517. PMID 19390808
- Aniridia Foundation International - AFI
- Aniridia Europe
- GeneReviews/NCBI/NIH/UW entry on Aniridia
- OMIM entries on Aniridia
- GeneReviews/NIH/NCBI/UW entry on Wilms Tumor Overview
- Vision For Tomorrow - VFT
- Cure Aniridia - Funding and Finding a cure
- Canadian Aniridia Foundation
|Wikimedia Commons has media related to Aniridia.|